Fedratinib + Nivolumab combination

Current understanding

To be populated as evidence accumulates.

Evidence log

• 2026-04-08 — Fedratinib in Combination With Nivolumab: Phase II open-label single-arm trial (trial-early) investigating fedratinib + nivolumab in myelofibrosis patients with resistance or suboptimal response to prior JAK inhibitor therapy — first-in-class JAK2 + PD-1 checkpoint inhibitor pairing in this setting. (novelty: 4)

Open questions

Related